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Abstract
Background: This study was conducted to determine the efficacy of the antimalarial artemisinin-based combination therapy
(ACT) artesunate +sulfamethoxypyrazine/pyrimethamine (As+SMP), administered in doses used for malaria, to treat
Schistosoma haematobium in school aged children.
Methodology/Principal Findings: The study was conducted in Djalakorodji, a peri-urban area of Bamako, Mali, using a
double blind setup in which As+SMP was compared with praziquantel (PZQ). Urine samples were examined for Schistosoma
haematobium on days 21, 0, 28 and 29. Detection of haematuria, and haematological and biochemical exams were
conducted on day 0 and day 28. Clinical exams were performed on days 0, 1, 2, and 28. A total of 800 children were included
in the trial. The cure rate obtained without viability testing was 43.9% in the As+SMP group versus 53% in the PZQ group
(Chi
2=6.44, p=0.011). Egg reduction rates were 95.6% with PZQ in comparison with 92.8% with As+SMP, p=0.096. The
proportion of participants who experienced adverse events related to the medication was 0.5% (2/400) in As+SMP treated
children compared to 2.3% (9/399) in the PZQ group (p=0.033). Abdominal pain and vomiting were the most frequent
adverse events in both treatment arms. All adverse events were categorized as mild.
Conclusions/Significance: The study demonstrates that PZQ was more effective than As+SMP for treating Schistosoma
haematobium. However, the safety and tolerability profile of As+SMP was similar to that seen with PZQ. Our findings
suggest that further investigations seem justifiable to determine the dose/efficacy/safety pattern of As+SMP in the
treatment of Schistosoma infections.
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Introduction
An estimated 200 million individuals worldwide are living with
schistosomiasis, the second parasitic disease after malaria in terms
of socioeconomic and public health importance [1,2]. From the
estimated global burden of 50 million DALYs (disability adjusted
life years) for the cluster of neglected diseases, schistosomiasis
accounts for 1,760,000 DALYs [3]. Since no vaccine is available at
this time, reduction of morbidity has become the most important
goal for all schistosomiasis control programs. Currently, the
standard first line treatment is praziquantel (PZQ). This drug is
easy to administer and is active against all Schistosoma species.
However, low cure rates have been observed in several regions
throughout Africa after praziquantel treatment [4,5]. In highly
endemic areas, treatment with the standard dose of 40 mg/kg may
no longer suffice. As a consequence, higher doses may be given
over a longer period of time, which may lead to the appearance of
more side effects, which in turn may have a major impact on
treatment compliance, as well as an increased risk of resistance.
Besides, praziquantel is only active against the adult forms of the
parasite, and does not clear young developing forms in the patient.
Therefore, egg production will eventually resume, and infection
continues to spread, making control efforts difficult and of limited
efficacy.
Artemether and artesunate, derivates of artemisinin (the
Chinese drug qinghaosu) are widely and effectively used against
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(ACT) [6]. Co-infection with schistosomes is common in malaria
endemic areas. For example, in Mali, 76.6% of Schistosoma
haematobium infected children develop malaria [7]. The artemisi-
nins have interesting antischistosomal properties, in particular
against the juvenile, 2- to 3- week – old, parasites [8]. From the
limited number of studies (in vivo & in vitro) conducted on Schistosoma
spp with artemisinin derivatives, higher cure rates were obtained
when artesunate was used in combination with praziquantel in
comparison to cure rates of artemether or artesunate alone
[9,10,11]. Although several publications from pilot studies in
humans demonstrate the effects of artemisinin derivatives used
alone [12,13], pilot studies that were conducted with ACTs seem
to demonstrate even higher efficacy [11,14,15]. These findings
suggest an interesting synergy, although more elaborate and
statistically powerful trials are necessary to elucidate these findings
[16].
In this study, the safety and effect of the ACT Co-Arinate
FDCH (combination of artesunate with sulfamethoxypyrazine and
pyrimethamine (As+SMP)) and praziquantel (PZQ) on the cure
rate and egg reduction rate of Schistosoma haematobium, the most
widely distributed species in Sub-Saharan African countries, were
compared in a double blind controlled trial.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study site
The trial was carried out between August 2007 and October
2007 in Djalakorodji, a peri-urban area of Bamako, the capital of
Mali. The village is situated to the north of Bamako and has
28,000 inhabitants. Numerous temporary streams, created by
seasonal rains, intersect the village in several locations. Although
these streams dry up after the rainy season (March - April) they are
used by the population for multiple activities such as laundry,
dishwashing, fishing, bathing and recreation. They constitute an
excellent breeding place for snails, the intermediate hosts
necessary for completion of the Schistosoma life cycle. Consequently,
repetitive Schistosoma infections are common, particularly in
children. Risk of contamination is especially high during the
period following the rainy season until these temporary water
sources have dried up. These excellent conditions for Schistosoma
proliferation lead to incidences of up to 70% in schoolchildren
[17].
Study design
This is a double-blind, controlled clinical trial in children, aged
6 to 15 years. The study was designed to determine the efficacy of
the antimalarial ACT As+SMP, administered in doses used for
malaria, to treat S. haematobium and to determine the safety profile
during treatment and follow up. The trial was approved by the
Institutional Review Board of the Faculty of Medicine, Pharmacy
and Dentistry, University of Bamako, Mali. The study objectives
were explained in detail to the authorities of the village. After
receiving approval for conducting the study in the community, all
the children’s parents or guardians were invited to enrol their
children into the study at the nearest schools according to a
schedule broadcasted on the local radio as well as by the local
informer (‘Le Crieur Public’). During the meeting, detailed
information was provided about the goals, procedures and
potential risks of the study. After obtaining individual written
informed consent, all children were invited to bring urine samples
in a plastic container for examination. The following day, those
children who were excreting S. haematobium eggs were eligible for
enrolment into the study. To confirm their positive diagnosis for
schistosomiasis, the enrolled children were asked to provide
another urine sample for examination the following day and the
mean egg count of the two samples was considered as the baseline
intensity of infection. At the beginning of the trial, the study
physician carried out a full clinical examination of all schistosome
positive children, including assessment of liver and spleen
enlargement and anaemia. The children included into the study
were between 6 and 15 years old, appeared healthy at enrolment
as assessed by the study physician and suffered from S. haematobium
infection (excreting eggs in urine). They were all residents of
Djalakorodji, were able to receive oral treatment, suffered of no
apparent chronic or debilitating conditions and the respective
parent/legal guardian gave written informed consent to partici-
pate in the study, after they had been provided with detailed study
information by the investigators. The following exclusion criteria
applied: weighing more than 50 kg, pregnant or lactating at the
time of the study, presence of severe illness such as cerebral
cysticercosis or signs of severe malnutrition (defined as children
with weight/height ratio below 3 standard deviations or below
70% of the median of the Word Health Organization’s (WHO)
standardized reference values, or still with symmetrical oedema
affecting both feet). Children were also excluded if they were
hypersensitive to As, SMP or PZQ, used another ACT or anti-
schistosomal drug during the study, or previously participated in
another similar study.
The cure rate for the PZQ group was assumed to be 75% (60–
95%), while the cure rate in the As+SMP treatment group was
estimated at +10% in comparison to the PZQ group. With 90%
power and a two-sided type 1 (a) error of 5%, we calculated that
354 patients were needed in each of the treatment arms. 46
additional children were included in each arm to correct for loss to
follow-up and non compliance. A total number of 800 children
were enrolled in the trial, with 400 children randomized into each
arm. Block randomization was used to allocate the patients to the
two treatment arms, and was blinded to the treating physician and
his team, as well as to the patient.
One arm of the study received PZQ (treatment B) on the first
day of treatment and As+SMP matched placebo (treatment D) on
the second day of treatment. The second arm received PZQ
matched placebo (treatment A) on the first day of treatment and
As+SMP (treatment C) on the second day of treatment.
Treatment allocation was carried out using an envelope system,
containing either ‘‘treatment A/C’’ or ‘‘treatment B/D’’. All
tablets were administered under direct medical supervision, which
assures compliance to the treatment. The random allocation
sequence was computer generated in Belgium. The participants
were enrolled by the clinical investigators and they were assigned
to their treatment group by the study pharmacist on site
(Djalakorodji, Mali).
Co-Arinate FDCH was administered as a 24 hour therapy with
3 tablets. Each tablet contains 100 mg artesunate +250 mg
sulfamethoxypyrazine/12.5 mg pyrimethamine. This drug is
now being introduced in many African countries for the treatment
of malaria. Doses administered in this trial were equal to the doses
that are used for the treatment of malaria. The drug’s safety and
efficacy for treating malaria has been demonstrated in several
studies, most recently in a large multicenter trial carried out in 4
different regions throughout Africa [18]. Due to the established
safety profile, simplicity (one fixed dose combination tablet) and
short administration time (24 hours) of Co-Arinate FDCH, the
As+SMP versus PZQ on Sh
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first line standard treatment for schistosomiasis infection in Mali,
was administered at the standard dose of 40 mg/kg.
Laboratory procedures
At screening, each child provided one urine sample. A second
sample was collected the following day before inclusion in the trial.
Samples were taken between 10 am and 2 pm, and children were
asked to run 3 laps before donating their samples. Appearance
(macroscopic aspect) of the urine samples was reported and
haematuria was checked (HemastixH, Siemens Diagnostics,
Belgium). At screening and at day 28 blood were obtained to
measure White Blood cell Count 10
3/mL (WBC), Red Blood cell
Count 10
3/mL (RBC), Haemoglobine g/dl (Hgb), Haematocrit %
(Ht), Mean Corpuscular Volume fl (MCV), Mean Corpuscular
Haemoglobin Concentration g/dl (MCHC), Mean Corpuscular
Haemoglobin pg (MCH), Platelets 10
3/mL, Lymphocytes 10
3/mL,
Alanine Aminotransferase U/L (ALT), Aspartate Aminotransfer-
ase U/L (AST) and creatinine mM/L).
Quantitative urine analysis was performed, using a filter
technique with WhatmanH filters. Two separate microscope filters
were prepared for each sample, and evaluated by 2 independent,
experienced microscopists. Data quality control for inter-observer
variability was addressed by re-reading 10% of all the slides,
picked out at random. If the first reading was positive and the
second reading positive with a difference of less than 20%, mean
number of eggs per 10 mL urine was calculated. If there was a
difference between the two readers of 20% or more, a third reader
was assigned to re-read the slides.
Infected children who were excluded from the study due to any
of the above mentioned exclusion criteria, were treated at a
standard recommended dose of 40 mg/kg PZQ.
Children were asked to come back and visit the team for
treatment evaluation on 28 and 29 days after drug administration.
Children who were not present on the evaluation days were
actively searched for and brought to the centre by local guides.
Two urine samples were collected from each child. If eggs were
still present in these urine samples, a viability check was carried
out. This test consists of checking for moving organelles of the
miracidium inside the egg shell, hatching miracidia (in case of
rupture of the egg shell) or beating of flame cellular. All dark eggs
were considered as non viable. If all eggs in a sample were
determined to be non viable (dark eggs or eggs without any of the
viability characteristic listed above), the samples were considered
to be egg negative.
Outcome measurements
Study primary outcome was measured by treatment cure rate
and egg reduction rate. Egg reduction rate was calculated as: [1 -
(geometric mean of egg counts per 10 mL of urine after treatment
divided by geometric mean of egg counts per 10 mL of urine
before treatment)] 6100. Secondary outcomes were measured by
(1) changes in urine appearance (before mixing the urine sample
with the staining solution, the visual appearance of each urine
sample was noted as being clear, cloudy or blood stained) before
and after treatment, (2) changes in haematuria (using HemastixH)
before and after treatment and (3) patients’ opinion towards the
different treatment arms. The patient’s opinion on the treatment
was evaluated by using a short questionnaire. All adverse events
were recorded following the days of treatment, all children were
invited to come to the centre for two days of active follow-up, as
well as at any time during the study period for adverse events (sign
or symptoms). Investigators were permanently present at the study
site. Adverse events are considered drug related if the same
adverse events were not reported at the first presentation to the
clinic during screening and the clinician did not find another
explanation.
Data management and statistical analysis
Data were double entered, validated using Microsoft ACCESS
and analyzed with SPSS 12.0 for Windows. The intention-to-treat
(ITT) analysis included all the randomized patients, excluding one
case who received both investigational drugs. The ITT analysis
was used for analysis of baseline comparison and adverse events.
Per-protocol (PP) analysis was used for baseline comparison and
for efficacy evaluation. Pearson Chi-square test, Yates Chi-square
test or Fisher Exact tests were used to compare categorical
variables. Mann-Whitney U test and Unpaired Student t-test were
used to assess differences between treatment arms in the means for
continuous variables. The McNemar paired chi-square test was
used to compare the frequency of haematuria and the proportion
of biological parameter normal values before and after treatment
in each treatment arm. Wilcoxon T test was used to compare
laboratory values before and after treatment administration.
Results
Out of a total of 3033 children (age range 6–15 years) screened
for infection, 2233 children did not meet our inclusion criteria. A
total of 392 children completed the study in the As+SMP treatment
arm. Three children were lost to follow-up, in 3 other cases the
protocol was violated, and 2 patients chose to withdraw from the
study. In the PZQ treatment arm, one patient received both
medications and was withdrawn from analysis. Six children were
lost to follow-up, 1 patient voluntarily withdrew from the study, and
the protocol was violated in 4 children. A total of 389 children
completed the study in the PZQ treatment arm (Figure 1).
Demographics
At enrolment, the two study treatment groups were similar with
regard to age, sex, ethnicity, weight, height and egg count per
10 mL of urine, p.0.05. The mean age was 10.45 years, and
35.8% of all the patients were female (Table 1).
Efficacy
Urine aspect (data not shown). Microscopic haematuria
and macroscopic aspect of urine did not significantly differ
between the two treatment groups (Per protocol analysis) before as
well as after the treatment with PZQ or As+SMP.
Egg counts per 10 mL of urine. The geometric mean of egg
count in each group before treatment was comparable 42.2 in
As+SMP group and 41.2 in PZQ group (Table 1). In terms of
presence of eggs in urine after treatment, the cure rate in the PZQ
group was 53%. After correction for egg viability, the cure rate
was determined to be 97.7%. In the As+SMP treatment group, the
cure rate was 43.9% and 81.4% after correction for egg viability.
The cure rates before and after egg viability testing were higher in
the PZQ group than in the As+SMP group, respectively Chi-
square =6.44, p-value =0.011 and Chi-square =55.26, p-value
,0.001 (Table 2). After treatment the geometric mean of egg
counts without viability test was 2.9 under As+SMP versus 1.8
under PZQ, Mann-Whitney U test p,0.001.
The egg reduction rate without viability test under PZQ
treatment was 95.6% in comparison to 92.8% under As+SMP
treatment Chi-square =2.76, p=0.096.
The geometric mean of egg counts after viability test was
comparable: 1.1 for As+SMP versus 1.0 for PZQ. The egg
reduction rate after viability test under PZQ treatment was 97.6%
As+SMP versus PZQ on Sh
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=0.05, p=0.829.
Haematuria: The frequency of haematuria on day 28 was 49.7%
(193/388) under PZQ treatment in comparison to 57.5% (225/
391) under As+SMP treatment, Chi-square=4.77, p-val-
ue=0.028. Within each treatment arm, haematuria was less
frequent in children on day 28 in comparison to day 0 (57.5%
(225/391) versus 83.1% (324/390) for As+SMP treatment group
and 49.7% (193/388) versus 87.6% (339/387) for PZQ), p,10
26.
Patient opinion (data not shown). Both treatments were
found to be easy to use and patient opinion on the number of
tablets to be taken, treatment intake and administration of drugs
between the two treatments did not vary significantly between the
two treatment arms.
Figure 1. Trial profile. Out of a total of 3033 children (age range 6–15 years) screened for infection, 2233 children did not meet inclusion. A total of
392 children completed the study in the As/SMP treatment arm. Three children were lost to follow-up, in 3 cases the protocol was violated, and 2
patients chose to withdraw from the study. One patient assigned to the PZQ treatment arm received both medications and was withdrawn from
analysis. Six children were lost to follow-up, 1 patient voluntarily withdrew from the study, and the protocol was violated in 4 children. A total of 389
children completed the study in the PZQ treatment arm (Figure 1).
doi:10.1371/journal.pone.0006732.g001
As+SMP versus PZQ on Sh
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Adverse events. After treatment, the proportion of
participants who experienced adverse events related to medication
was 0.5% (2/400) in the As+SMP treatment arm versus 2.3% (9/
399) in the PZQ group, Chi-square=4.53, p-value=0.033.
Abdominal pain and vomiting were the most frequent adverse
events for both treatment arms. Dizziness and headache were also
observed inthe PZQgroup. Alladverseeventswere mild (Table3).
Laboratory evaluation. Comparison of biological param-
eters between the two treatment arms shows that all the
parameters (White Blood cell Count 10
3/mL (WBC), Red Blood
cell Count 10
3/mL (RBC), Haemoglobine g/dl (Hgb), Haematocrit
% (Ht), Mean Corpuscular Volume fl (MCV), Mean Corpuscular
Haemoglobin Concentration g/dl (MCHC), Mean Corpuscular
Table 1. Baseline characteristics.
As+SMP N=392 PZQ N=389
Age
Mean Age 6 SD 10.462.4 10.562.5
Range (Min, Max) 9.4 (6, 15.4) 9.2 (6, 15.2)
Median 10.2 10.5
Sex
Sex Male 251 252
Sex Female 141 137
Ethnicity
Bambara 211 220
Sarakole 41 30
Malinke 27 39
Peulh 24 23
Dogon 16 16
Senoufo 12 11
Dafing 11 13
Bobo 16 7
Sonrhaı ¨ 13 14
Kakolo 8 5
Others 13 11
Weight
Mean Weight 6 SD 27.767.5 28.067.3
Range (Min, Max) 33 (17, 50) 34 (16, 50)
Median 26.0 27
Height
Mean Height 6 SD 133.5612.5 133.7611.8
Range (Min, Max) 58 (108, 166) 61 (108, 169)
Median 133.0 133.0
Eggs count Day 0*
Geometric Mean Eggs 40.9 41.4
Range (Min, Max) 1458 (2, 1460) 1382 (2, 1384)
Median 42.2 41.2
Haematuria detected by Hematix
Haematuria + 324 339
Haematuria 2 66 48
Total 390 387
Urine macroscopic aspect
Hematic + 160 177
Hematic 2 232 212
Total 392 389
*Mann-Whitney U test.
doi:10.1371/journal.pone.0006732.t001
Table 2. Repartition of cure rate by treatment arm before
and after viability test on day 28.
As+SMP PZQ
without
viability
testing
with
viability
testing
without
viability
testing
with
viability
testing
–S. haematobium
negative children
172 319 206 380
S. haematobium
positive children
220 73 183 9
Cure Rate % 43.9 81.4 53.0 97.7
Total number of
children treated
392 389
doi:10.1371/journal.pone.0006732.t002
Table 3. Number of adverse events per treatment group.
(R=related, NR=Not related, Tot=total).
As+SMP PZQ
R NR Tot R NR Tot
Abdominal pain 1 7 37 41 4 95 0
Dizziness 0 1 71 73 1 72 0
Headache 0 6 16 11 6 26 3
Vomiting 1 104 105 4 30 34
Anal pruritus 011044
Anorexia 033000
Boil 011000
Chills 011011
Convulsions 011000
Cough 0 2 82 80 2 42 4
Conjunctivitis 011000
Dermatosis 044044
Diarrhoea 099088
Hypersalivation 011000
Local skin
infections
011011
Nausea 077055
Otitis 011011
Palor 033011
Pruritus 000022
Rhinobronchitis 011000
Rhinorrhea 0 1 21 20 9 9
Sore throat 011022
Thoracic pain 033055
Urinary burn 011011
Wound 044077
TOTAL 2 339 341 9 233 242
doi:10.1371/journal.pone.0006732.t003
As+SMP versus PZQ on Sh
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As+SMP PZQ p*
Mean6SD Med Min Max NAV Mean6SD Med Min Max NAV
WBC (10
3/mL)
Day 0 7.362.1 6.9 3.4, 17.6 46 7.362.1 7 2.8, 18.0 43 0.622
Day 28 7.762.6 7.2 3.0, 17.9 78 7.162.0 6.8 3.1, 20.6 43 0.007
p** 0.005 0.005
RBC (10
3/mL)
Day 0 4.561.1 4.4 2.8, 24.0 26 4.460.5 4.4 1.8, 6.9 24 0.675
Day 28 4.460.4 4.4 3.2, 5.7 15 4.460.4 4.4 3.0, 6.1 22 0.628
p** 0.025 0.005
Hgb (g/dl)
Day 0 11.261.4 11.4 7.4, 13.9 64 11.161.5 11.4 3.7, 14.3 63 0.746
Day 28 11.460.9 11.4 7.9, 14.5 18 11.360.9 11.4 7.4, 13.4 17 0.981
p** 0.488 0.376
Ht (%)
Day 0 35.563.1 35.6 25.3, 44.3 21 35.363.3 35.6 14.9, 43.0 18 0.57
Day 28 35.162.6 35.3 27.3, 42.6 10 34.962.6 35 26.9, 41.8 11 0.537
p** ,0.001 0.001
MCV (fL)
Day 0 80.865.7 80.8 60.9, 98.2 20 80.366.4 81.2 57.1, 99.2 38 0.568
Day 28 80.265.6 80.5 60.0, 94.0 23 80.266.0 81.1 56.9, 95.5 32 0.706
p** 0.011 0.339
MCHC (g/dl)
Day 0 31.562.8 32.3 21.7, 35.5 100 31.463.1 32.2 21.1, 50.3 102 0.61
Day 28 32.361.2 32.4 26.3, 36.1 33 32.461.2 32.4 26.4, 35.4 31 0.486
p** 0.038 ,0.001
MCH (pg)
Day 0 25.463.0 25.9 14.9, 31.7 60 25.363.5 26 13.1, 41.7 73 0.827
Day 28 25.962.4 26.3 15.8, 39.1 27 25.962.4 26.4 16.8, 31.2 33 0.557
p** 0.527 0.003
Platelets (10
3/mL)
Day 0 364.2690.2 359 36.0, 804.0 53 363.3696.7 354 142.0, 1000 54 0.522
Day 28 338.6685.6 330 94.0, 799.0 30 347.6691.2 338.5 83.0, 965.0 46 0.206
p** ,0.001 ,0.001
Lymphocytes (10
3/mL)
Day 0 2.960.8 2.7 1.2, 6.3 2.860.8 2.8 1.2, 7.3 0.911
Day 28 2.960.8 2.8 1.3, 5.6 2.961.0 2.8 1.1, 14.1 0.403
p** 0.63 0.169
ALT (U/L)
Day 0 29.8616.5 25 6.0, 146.3 31 28.8615.8 23.7 9.1, 118.5 31 0.172
Day 28 26.4617.3 23.1 6.2, 274.7 14 26.1613.6 22.9 3.6, 138.7 18 0.682
p** ,0.001 0.004
AST (U/L)
Day 0 43.1626.6 38.4 15.2, 451.0 40.4622.3 36.3 9.7, 398.0 0.109
Day 28 43.9620.9 39.3 14.7, 194.2 44.3620.8 39.1 9.9, 173.6 0.973
p** 0.165 0.016
Creatinin (mM/L)
Day 0 75.8634.1 72 10.3, 621.0 374 73.7618.9 70.9 37.2, 148.1 377 0.52
Day 28 84.7624.6 82.3 26.0, 313.1 385 86.9626.8 83.2 35.8, 228.9 383 0.59
p** ,0.001 ,0.001
*Mann-Witney U test.
**Wilcoxon T test for paired samples.
doi:10.1371/journal.pone.0006732.t004
As+SMP versus PZQ on Sh
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3/mL, Lymphocytes 10
3/mL,
Alanine Aminotransferase U/L (ALT), Aspartate Aminotransferase
U/L (AST) and creatinine mM/L) were similar on day 0. After
treatment (Day 28) only the mean WBC increased significantly
under As+SMP treatment (7.762.6 in As+SMP, versus 7.162.0 in
the PZQ group), p=0.007.
Table 4 indicates that, within the As+SMP group, the mean
WBC, MCHC and creatinine levels increased significantly over
time, while the mean RBC, Ht, MCV, Platelets and ALT
decreased significantly after treatment. Hgb, MCH, lymphocyte
count and AST levels remained stable. Within the PZQ group, the
mean MCHC, MCH, AST and creatinine values increased
significantly in comparison to the mean values of WBC, RBC, Ht,
Platelet counts, and ALT, which decreased significantly. Hgb,
MCV and lymphocyte counts did not change after treatment.
Discussion
The efficacy and safety of the antimalarial ACT As+SMP,
administered in the doses used for the treatment of malaria, were
compared to the efficacy and safety of PZQ, the standard
treatment for schistosomiasis, in children aged 6 to 15 years.
As+SMP induced a egg reduction rate of 92.8% compared to
95.6% obtained with PZQ. The cure rate without viability test
was 43.9% in the As+SMP group versus 53% in the PZQ group
(Chi
2=6.44, p=0.011), meaning that PZQ was more effective
than As+SMP for treating S. haematobium infections. The cure rate,
based on the absence of viable eggs, was 81.4% in the As+SMP
group versus 97.7% in the PZQ group (Chi
2 =55.26,p,0.001).
However, the latter 2 figures have to be interpreted with care,
since the viability test was used only after completion of treatment
in the two groups, and a control group was not included in the
analysis. In addition, the viability test, as performed in this study,
is not routinely used for diagnosis and treatment evaluation, and
to date has never been used in drug evaluation trials in S.
haematobium infected patients [19] .T h ep r e s e n c eo fv i a b l ee g g si n
the urine corresponds to an active infection, which may be due to
reduced strain susceptibility to the drug, questions about drug
quality, drug bioavailability, to high initial intensity of infection or
to pre-patent infection at the time of screening [4]. For example,
for PZQ, studies in which the recommended doses were used
have recorded cure rates from 60% to 90% for S. haematobium
infections [20,21,22]. In addition, PZQ has reduced S.
haematobium worm burdens in a moderately endemic situation in
Burundi by 94% [23]. Finally, a recent study in Zimbabwe
showed a cure rate of 88.5% with PZQ treating S. haematobium-
infected persons [24].
In this study, PZQ was more efficacious to reduce haematuria
during S. haematobium infections in comparison to As+SMP,
administered in doses used for the treatment of malaria. The
repartition of haematuria on day 28 between the two groups, as
determined by the HemastixH test, shows a statistical difference
(49.7% under PZQ treatment versus 57.5% under As+SMP, Chi-
square=4.77, p=0.028). This difference is most likely related to
the difference in cure rate observed between the two treatment
arms.
The safety and tolerability profile of As+SMP was similar to the
profile seen with PZQ. All clinical adverse events were graded
mild and were resolved during the 2 active follow-up days.
No serious adverse event was recorded with any one of the
treatments administered, as documented in previous studies
[21,25,26,27,28,29]. Our study shows that abdominal pain
and vomiting were the most frequent adverse events for both
treatment arms. Related adverse events were more frequent in the
PZQ group than in the As+SMP group, p-value =0.033. Previous
studies have observed similar adverse events in patients who were
being treated with praziquantel [4,24,30,31,32].
Overall, the means of all laboratory parameters were normal on
days 0 and 28, except for the creatinine for both treatment arms.
This can be explained by the effect of S. haematobium on the kidneys
[33,34,35].
Conclusion
Although the safety and tolerability profiles of both treatment
arms are similar, PZQ was more effective than As+SMP in this
clinical set up. However, the doses of As+SMP that were used in
this trial are doses commonly used for the treatment of malaria.
Further research into correct dosing for this specific indication
may be recommendable. It will be interesting to evaluate the
efficacy and safety of As+SMP on other Schistosoma species, such as
Schistosoma mansoni, as well as the effect of the combination of
As+SMP and PZQ on both S. haematobium and S. mansoni.
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